Over the current book year the total revenue will be 5,91 million Icelandic Krona (consensus estimates). This is rather significant more than 2019's revenue of 4,11 million Icelandic Krona.
The analysts expect for 2020 a net loss of 208 million Icelandic Krona. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a loss per share of 1,49 Icelandic Krona. The price/earnings-ratio therefore equals -8,33.
Analysts don't expect the company to pay a dividend. The average dividend yield of the pharmaceutical companies is a poor 0,19 percent.
Inovio Pharmaceuticals Inc's market capitalization is based on the number of outstanding shares around 1,21 billion Icelandic Krona. The Inovio Pharmaceuticals Inc stock was the past 12 months quite volatile. Since last October the stock is even 508 percent higher. This year the stock price moved between 2 and 34 mark.
Click here for dividend Inovio Pharmaceuticals Inc.
Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.